Jódar E - Search Results

1

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. Among authors: jodar e. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.

2

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.

Leiter LA, Bain SC, Hramiak I, Jódar E, Madsbad S, Gondolf T, Hansen T, Holst I, Lingvay I. Leiter LA, et al. Among authors: jodar e. Cardiovasc Diabetol. 2019 Jun 6;18(1):73. doi: 10.1186/s12933-019-0871-8. Cardiovasc Diabetol. 2019. PMID: 31167654 Free PMC article.

3

Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).

Jódar E, Michelsen M, Polonsky W, Réa R, Sandberg A, Vilsbøll T, Warren M, Harring S, Ziegler U, Bain S. Jódar E, et al. Diabetes Obes Metab. 2020 Aug;22(8):1339-1347. doi: 10.1111/dom.14039. Epub 2020 Apr 27. Diabetes Obes Metab. 2020. PMID: 32227613 Free PMC article. Clinical Trial.

4

Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.

Vilsbøll T, Blevins TC, Jodar E, Poulter N, Tentolouris N, Ross Agner BF, Lehmann L, Leiter LA. Vilsbøll T, et al. Among authors: jodar e. Diabetes Obes Metab. 2019 Jun;21(6):1506-1512. doi: 10.1111/dom.13675. Epub 2019 Apr 8. Diabetes Obes Metab. 2019. PMID: 30785655 Free PMC article.

5

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I. Aroda VR, et al. Among authors: jodar e. Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4. Diabetes Metab. 2019. PMID: 30615985 Review.

6

Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.

Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jódar E. Lingvay I, et al. Among authors: jodar e. Diabetes Obes Metab. 2018 Jan;20(1):200-205. doi: 10.1111/dom.13043. Epub 2017 Jul 31. Diabetes Obes Metab. 2018. PMID: 28643425 Free PMC article. Clinical Trial.

7

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group. DeVries JH, et al. Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14. Diabetes Care. 2012. PMID: 22584132 Free PMC article. Clinical Trial.

8

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.

Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Garvey WT, et al. Among authors: jodar e. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10. Nat Med. 2022. PMID: 36216945 Free PMC article. Clinical Trial.

9

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).

Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z. Pozzilli P, et al. Among authors: jodar e. Diabetes Obes Metab. 2017 Jul;19(7):1024-1031. doi: 10.1111/dom.12937. Epub 2017 Apr 10. Diabetes Obes Metab. 2017. PMID: 28294499 Clinical Trial.

10

Incidence and costs of cardiovascular events in Spanish patients with type 2 diabetes mellitus: a comparison with general population, 2015.

Jodar E, Artola S, Garcia-Moll X, Uría E, López-Martínez N, Palomino R, Martín V. Jodar E, et al. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001130. doi: 10.1136/bmjdrc-2019-001130. BMJ Open Diabetes Res Care. 2020. PMID: 32747385 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page